BioNet News 30 Jul 2024 Transplacental transfer of maternal antibodies following immunization with recombinant pertussis vaccines during pregnancy: Real-world evidence Pertussis, caused by Bordetella pertussis, is a highly contagious respiratory disease that poses a significant risk to young infants, resulting in both severe morbidity… Pantitra
BioNet News 17 May 2024 First study to assess placental transfer of maternal antibodies after immunization with recombinant pertussis vaccines during pregnancy Pertussis (whooping cough), caused by Bordetella pertussis, is a highly contagious respiratory disease responsible for severe morbidity and about 4%… Supachai
BioNet News 05 Apr 2024 BioNet aP on its way to support Thailand’s Universal Coverage Scheme, managed by NHSO The shipment is underway. Our acellular pertussis vaccines (aP) are officially on the move, heading to support the Universal Coverage… Pantitra
BioNet News 12 Jan 2024 Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines Recombinant acellular pertussis (ap) vaccines containing genetically inactivated pertussis toxin (PTgen) and filamentous hemagglutinin (FHA) with or without tetanus (TT)… Pantitra
BioNet News 12 Dec 2023 Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines Highlights • Recombinant pertussis vaccine is safe for both mother and newborn. • There is effective transplacental antibody transfer to… Supachai
BioNet News 22 Jun 2023 A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women Highlights • Recombinant acellular pertussis vaccine is safe and immunogenic in pregnant women. • Vaccine formulations containing PTgen were non-inferior… Supachai
BioNet News 05 Apr 2022 A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age A phase 2 randomized-controlled safety and immunogenicity trial evaluating different doses of recombinant acellular pertussis vaccine containing genetically-inactivated pertussis toxin… Pantitra
BioNet News 23 Jul 2021 Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccines Recombinant pertussis vaccines inducing long-lasting immune responses could help to control the rise in pertussis. We here report on persisting… Pantitra
BioNet News 05 Dec 2020 Enhanced post-licensure safety surveillance of a new recombinant acellular pertussis vaccine licensed as a monovalent (aP, Pertagen®) and tetanus, reduced-dose diphtheria combination (TdaP, Boostagen®) vaccine for immunization of adolescents and adults in Thailand A new generation of recombinant acellular pertussis vaccine containing genetically inactivated pertussis toxin (PTgen) was licensed as a monovalent pertussis… Pantitra
